TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A MedPage Today opinion article by physician Hamayle Saeed describes being screened for diabetes at a BMI of 23 under American Diabetes Association guidance, while being told she did not meet the BMI criteria for a GLP-1 weight-loss drug. The account highlights a policy gap: Asian-specific clinical risk thresholds do not necessarily carry over to drug labels, trial criteria or insurer authorization rules.
A South Asian physician says she was screened for diabetes at a BMI of 23 under American Diabetes Association guidance but was denied a GLP-1 weight-loss drug at a BMI of 26.5 because she did not meet the commonly applied 30 BMI threshold or the alternative threshold of 27 with a weight-related condition. In an October 31 MedPage Today opinion article, Hamayle Saeed argues that the difference exposes a gap between risk assessment for Asian patients and the rules used to determine access to treatment.
Saeed, who identifies herself as a Pakistani American physician, says her doctor began diabetes screening in line with guidance that uses BMI 23 for Asian Americans, reflecting evidence that diabetes risk can emerge at lower body weights in Asian populations. She writes that she had a BMI of 26.5 and no diabetes when she asked about a GLP-1 receptor agonist for weight loss. She says she was not eligible under the thresholds applied to her: BMI 30, or BMI 27 with at least one weight-related condition.
The article describes the resulting mismatch as a difference between clinical risk guidance and coverage criteria. Saeed says diabetes screening guidance recognized her risk at a lower BMI, while the prior authorization process she faced did not use an Asian-specific adjustment. Her account is a personal report; the supplied material does not include a response from her insurer or identify the particular plan or medication involved.
Saeed also points to changes in public coverage. She reports that Medi-Cal dropped coverage for GLP-1 drugs prescribed for weight loss in January and MassHealth followed in July. She argues that tighter coverage can disproportionately affect people who sit near eligibility boundaries. The source material does not provide the policies or enrollment data needed to quantify how many patients were affected.
Screening Risk Does Not Guarantee Drug Access
The case illustrates how different rules can shape the same patient’s care: one threshold can prompt earlier screening, while another can block access to a medication. For readers, that distinction matters because a screening recommendation is not the same as a diagnosis, a prescription, or insurance approval. Each may rely on separate guidance and definitions.
Saeed’s broader concern is that conventional BMI cutoffs may understate risk for some Asian patients. If clinical definitions of obesity account for ethnicity but trial eligibility or insurer forms do not, patients could be assessed as at risk yet remain outside the criteria used for treatment coverage. The article raises a policy question, but it does not establish that every Asian patient with a lower BMI should receive a GLP-1 drug or that all insurers use identical criteria.
The debate also has practical stakes as public programs revise coverage. A change in eligibility can affect whether patients can obtain treatment for weight management, even when a clinician sees elevated metabolic risk. The report does not assess the costs, benefits or budget effects of changing coverage thresholds; those questions remain part of the policy discussion.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Therabody SmartGoggles 2nd Gen Heated Eye and Temple Massager
As an affiliate, we earn on qualifying purchases.
How BMI Rules Diverged
The opinion article says the World Health Organization set lower action points for Asian populations in 2004, at BMI values of 23 and 27.5. It also cites a study of nearly 1.5 million adults in England that compared the BMI at which ethnic groups reached the diabetes risk observed among white adults at BMI 30. The reported estimates were 23.9 for South Asian adults and 26.9 for Chinese adults. These figures describe population-level findings; they do not determine an individual’s diagnosis.
Saeed says the mismatch has persisted partly because pivotal obesity-drug trials were designed around Western BMI definitions and their entry criteria influenced later practice. She cites a 2026 analysis of 352 GLP-1 trials, reporting that BMI cutoffs made fewer Asian American adults eligible than non-Asian American adults in the analysis. The article also describes a 2025 semaglutide study in South Korea and Thailand that enrolled participants using a local obesity threshold of BMI 25. The supplied account reports weight loss in the study but does not establish that its results automatically change U.S. prescribing or coverage rules.
The article notes that revised drug labels describe eligibility using obesity or overweight with a weight-related condition, while numerical BMI thresholds remain common in trial descriptions and insurer authorization forms. It also cites the ADA’s 2026 Standards of Care, which Saeed says call for clinicians to confirm excess adiposity using cutoffs appropriate to ethnicity and specifically name South Asian patients.
“The ADA guideline that flags me for annual diabetes screening and the prior authorization form that denies me the drug are describing the same 26.5.”
— Hamayle Saeed, MD, in a MedPage Today opinion article
Coverage Rules Still Vary
The account does not identify the insurer, the specific GLP-1 requested, or the exact wording of the prior authorization decision. It is therefore unclear whether the denial resulted solely from BMI criteria, from plan-specific rules, or from other coverage requirements. The article also does not establish how widely the experience is shared among Asian patients.
Drug-label wording, clinical recommendations and payer policies are distinct. The supplied source does not provide a full review of current FDA labeling or insurer contracts, and it does not confirm that every plan applies the same 30 and 27 BMI thresholds. Nor does it show that evidence from trials conducted in Asian countries has led to a change in U.S. coverage decisions.
Finally, BMI is only one measure used in evaluating health. The opinion article argues for ethnicity-aware definitions but does not settle how those definitions should be translated into prescribing standards, insurance rules or individual clinical decisions.
Policy Decisions Will Shape Access
The next developments will depend on whether clinical organizations, drug manufacturers and insurers align their definitions and coverage criteria with the population-specific evidence described in the article. Insurers may revise prior authorization forms or maintain existing numerical thresholds; the source does not report a specific announced policy change.
For patients and clinicians, the immediate question is what a particular plan requires and how it defines obesity or weight-related conditions. Saeed’s article calls attention to the gap, but does not report a resolution in her case or a forthcoming decision by her insurer. Any changes to coverage or clinical guidance remain unconfirmed.
Key Questions
What happened in the report?
Physician Hamayle Saeed wrote in MedPage Today that she was screened for diabetes under an Asian-specific BMI threshold but did not qualify for a GLP-1 weight-loss drug under the BMI criteria applied to her.
Why was screening recommended at a lower BMI?
The article says ADA guidance uses a BMI of 23 as a point for diabetes screening in Asian Americans because risk may occur at lower body weights. Screening guidance is not itself a diagnosis or a guarantee of medication coverage.
What BMI thresholds did Saeed say blocked access?
Saeed says she was told she did not meet the criteria of BMI 30, or BMI 27 with at least one weight-related condition. The source does not identify her insurer or confirm that every plan uses the same rules.
Does the report establish that all Asian patients should receive GLP-1 drugs at a lower BMI?
No. The article argues that risk assessment and coverage criteria may not reflect the same population-specific evidence. It does not establish a universal treatment threshold or say that BMI alone determines whether an individual should receive a drug.
Has U.S. insurance coverage changed in response?
The source describes coverage reductions in Medi-Cal and MassHealth and discusses newer clinical guidance, but it does not report a nationwide change to insurer eligibility rules or a confirmed policy update based on the evidence cited.
Source: medpagetoday.com
